



Universiteit
Leiden

The Netherlands

RAD51 as biomarker for the identification of homologous recombination deficient gynaecological carcinomas

Wijk, L.M. van

Citation

Wijk, L. M. van. (2024, June 12). *RAD51 as biomarker for the identification of homologous recombination deficient gynaecological carcinomas*. Retrieved from <https://hdl.handle.net/1887/3762708>

Version:

Publisher's Version

License:

[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from:

<https://hdl.handle.net/1887/3762708>

Note: To cite this publication please use the final published version (if applicable).

Stellingen behorende bij het proefschrift

RAD51 as biomarker for the identification of homologous recombination deficient gynaecological carcinomas

1. The perfect HRD test does not exist. - *This thesis*
2. Assessment of RAD51 foci in tumor samples offers a functional read-out for their homologous recombination status, which can be particularly informative in patients with recurrent disease where the potential reversion of the HRD phenotype might have occurred during chemo- or radiotherapy. - *This thesis*
3. Performing the RAD51-FFPE test to identify HRD cases, followed by “tumor-first” testing of tumor DNA for the presence of pathogenic variants in HR-related genes, is an efficient strategy to reliably select breast and ovarian cancer patients for PARPi/platinum-based therapy and referral to a clinical geneticist. - *This thesis*
4. To fully exploit the potential of PARPi/platinum-based therapy, all tumor types in which HRD can potentially be identified should be screened in routine diagnostics with an HRD test. - *This thesis*
5. Complete sequencing of tumor genomes should become part of good clinical practice since it will improve tumor diagnosis and patient care by identifying therapeutic targets and predicting drug resistance.
6. To achieve improved quality of life, it is important to empower patients to advocate for their own health and participate in shared decision-making processes (patient-centred healthcare).
7. Acceleration of scientific innovation is only possible when the scientific community starts valuing negative research results equally important as positive ones.
8. Prevention is better than cure; by improving gynaecological preventive care, the quality of life of all women can be improved while reducing healthcare costs.
9. De huidige samenwerking tussen alle betrokken partijen binnen de zorg (academie, zorgverleners, beleidsmakers, geneesmiddelenbedrijven en patiënten) moet opgeschaald worden om registratie en uitwisseling van FAIR (Findable, Accessible, Interoperable and Reusable) data ten behoeve van (Real-World Evidence; RWE) onderzoek en een verbetering van de kwaliteit van de zorg te realiseren. – *Geïnspireerd op het visiedocument van de Young Innovators of Medicine*
10. Creativity is key to success; we should not limit ourselves to what is available, but look into what would be possible. – *Inspired by “If you can dream it, you can do it” from Walt Disney*